Taking the contraceptive pill may reduce the risk of developing cancer

Taking the contraceptive pill does not increase a woman’s chances of developing cancer and may even reduce the risk for most women, according to a study published in BMJ today.

However there was an increased risk for women who used it for more than eight years.

Since its introduction in the early 1960s, more than 300 million women are thought to have used oral contraception. Although several studies have looked at the overall balance of cancer deaths associated with oral contraceptives, none have so far examined the absolute risks or benefits.

Researchers from the University of Aberdeen analysed data spanning a 36 year period from the Royal College of General Practitioners (RCGP) Oral Contraception Study which began in 1968.

The study recruited 46,000 women, with an average age of 29. Approximately half were using oral contraceptives; the other half had never taken it. Every six months their GP provided the study with information on the women's health. In addition, three quarters of the women were 'flagged' at the NHS central registries so that deaths and cancers were notified to the study even if women had left their recruitment GP.

Professor Philip Hannaford and colleagues used the data to calculate the risk of developing any type of cancer and the main gynaecological cancers combined. They also considered the effects of variables such as age, smoking and social class.

Given the length of the study a significant number of GPs had not been able to provide updates throughout the entire study period, for example if a woman moved out of the area of their doctor.

So Professor Hannaford and colleagues from the University of Aberdeen's Department of General Practice and Primary Care calculated the cancer risks using two sets of data. One that related to cancers reported while the women remained registered with their recruiting GP and whose information was more detailed (GP observation dataset). The second main study dataset which was larger, also included cancers notified by the central NHS registries after women had left their recruiting GP.

In both data sets there was no overall increased risk of cancer among pill users. When the GP observation dataset was used, women who had taken the pill at some time during their lives had a 3% reduced risk of developing any cancer. When the larger main dataset was used, the reduction was 12%.

A 12% reduction equates to approximately one fewer case of cancer for every 2,200 women who have used the pill for a year and 3% equates to one fewer case of cancer for every 10,000 women.

In the main dataset women on the pill had statistically significant lower rates of large bowel/rectal, uterine body and ovarian cancer. They also had a 29% reduced risk of developing one of the main gynaecological cancers. The data in the GP data set also showed a reduced risk of uterine and ovarian cancer.

The researchers did sound a note of caution. When the women were examined by how long they had used the pill, women who used it for more than 8 years – less than a quarter of pill users in the study - had a statistically significant increased risk of developing any cancer, in particular cervical and central nervous system cancer.

However the same women were at reduced risk of developing ovarian cancer. Evidence suggests that the protective effect of taking the pill lasts for at least 15 years after stopping.

The average duration of pill use in the study was 44 months.

The authors say that many women, especially those who used the first generation of oral contraceptives many years ago, are likely to find the results reassuring as they conclude:

Professor Hannaford, world expert on contraception, said: "These results show that in this UK cohort the contraceptive pill was not associated with an overall increased risk of any cancer, indeed it may produce an important net public health gain.

"Although the results relate to older types of pills, evidence from other studies suggests that currently available pills produce broadly similar effects.

"These findings will probably reassure most pill users living in the UK and their doctors. It should be remembered, however, that the balance of cancer risk may vary around the world, depending on patterns of pill usage and the incidence of different cancers."

Source: University of Aberdeen

Related stories:

Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
Just a numbers game? Making sense of health statistics
Presidential candidates use them to persuade voters, drug companies use them to sell their products, and the media spin them in all kinds of ways, but nobody - candidates, reporters, let alone health consumers - understands them. Health statistics fill today's information environment, but even most doctors, who must make daily decisions and recommendations based on numerical data - for instance, to calculate the risks of a certain drug or surgical intervention, or to inform a patient of the possible benefits versus harms of cancer screening - lack the basic statistical literacy they require to make such decisions effectively.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
Stem cells may solve mystery of early pregnancy breast cancer protection
The answer to why an early pregnancy seems to protect against breast cancer could rest with a decrease in stem cells found after animals have given birth, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Stem Cell.
Certain vitamin supplements may increase lung cancer risk, especially in smokers
Vitamin supplements do not protect against lung cancer, according to a study of more than 77,000 vitamin users. In fact, some supplements may even increase the risk of developing it.
Study: Birth Pill Protects Against Ovarian Cancer
The contraceptive Pill gives women substantial and long-lasting protection against ovarian cancer, according to a new report led by Oxford scientists published in The Lancet.
Putting risk in perspective: Do people make better decisions when they understand average risk?
If there were a pill that would cut your risk of breast cancer in half, would you take it? What if you were told your risk of breast cancer was already below average?
Vessel-thwarting antibody might help starve cancerous tumors
An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell.

News discussion:

Medicine & Health news